New febuxostat trial douses cardiovascular alarm
Investigators hope results from the FAST trial will lead to a rethink of boxed warnings on the drug.
Tag: ACR Convergence 2020
Study reassures on COVID-19 threat to rheumatology patients
Concern over elevated odds of severe disease might be unfounded, conference told.
Novel target for reducing flare in giant cell arteritis
An investigational monoclonal antibody that inhibits GM-CSF receptor alpha shows promise, researchers say.
JAK inhibitor ‘looks promising for ankylosing spondylitis’
A study shows improvements in patient pain and function with few serious adverse events, researchers say.
Warfarin might raise the risk of joint replacement: study
The analysis in people with AF suggests a NOAC might be the better option for those at risk of osteoarthritis, authors say.
JAK inhibitor ‘safe and effective’ for RA over 20 months
Extension trial in patients with inadequate response to methotrexate finds no new safety signals, researchers report.
Hydroxychloroquine shortages ‘hit patient health’
Up to a quarter of rheumatology patients were disadvantaged in some regions, a global survey suggests.
Steroid injections ‘don’t hasten progression of knee OA’
Patients can be reassured that the treatment will not precipitate the need for surgery, researchers say.
Hydroxychloroquine cardiac scare ‘debunked’
The study in patients with rheumatoid arthritis and lupus finds no association with prolonged QT interval.
Methotrexate ‘might benefit’ knee OA with inflammation
The agent could be considered if usual treatment fails, researchers say after a randomised trial.
